Treatment expectations and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy
Authors:
Open Access
- 2 May 2020
- journal article
- research article
- Published by Springer Nature in Journal of Neurology
- Vol. 267 (8) , 2398-2407
Abstract
Background: The antisense-oligonucleotide (ASO) nusinersen has recently been approved as the first genetically modifying therapy for 5q-associated spinal muscular atrophy (SMA) based on randomized sham-controlled trials in infants and children. The efficacy in adults with long disease history and advanced disease status is still widely unknown; the same applies to specific expectations of adult SMA patients and to what extent they are met and may impact outcome measures. Methods: In a longitudinal monocentric study in adult patients with SMA types 2–4, the Stanford Expectations of Treatment Scale (SETS) was assessed prior to and during nusinersen treatment. Treatment outcome was evaluated using patient-reported outcomes (PROs) as well as objectively quantifiable motor outcome measures. Results: Adult SMA patients had high expectations of nusinersen treatment effectiveness regarding increase in muscle strength and disease stabilization. Via PROs, 75% stated improvements in muscle strength, endurance and independence under therapy which was in line with slight improvements in quantifiable motor scores during a ten month observation period. In contrast, patients only expressed few negative expectations which further decreased during therapy. Conclusions: This study showed mainly positive treatment expectations and PROs in patients undergoing nusinersen treatment along with measurable functional improvement in adult SMA patients. Moreover, treatment expectations did not significantly influence outcome measures.Keywords
Funding Information
- German Research Foundation (DFG), PRACTIS – Clinician Scientist Program of Hannover Medical School
- Deutsche Gesellschaft für Muskelkranke
- Bundesministerium für Forschung, Technologie und Raumfahrt
- German-Israeli Foundation for Scientific Research and Development
- EU Joint Programme – Neurodegenerative Disease Research
- Hannover Medical School Young Faculty Program for Clinician Scientists
This publication has 31 references indexed in Scilit:
- Spinal Muscular AtrophyNeurologic Clinics, 2015
- Mapping the differences in care for 5,000 Spinal Muscular Atrophy patients, a survey of 24 national registries in North America, Australasia and EuropeJournal of Neurology, 2013
- Natural course of scoliosis in proximal spinal muscular atrophy type II and IIIa: descriptive clinical study with retrospective data collection of 126 patientsBMC Musculoskeletal Disorders, 2013
- Development of the Stanford Expectations of Treatment Scale (SETS): A tool for measuring patient outcome expectancy in clinical trialsClinical Trials, 2012
- Prospective cohort study of spinal muscular atrophy types 2 and 3Neurology, 2012
- Evaluation of SMN Protein, Transcript, and Copy Number in the Biomarkers for Spinal Muscular Atrophy (BforSMA) Clinical StudyPLOS ONE, 2012
- Spinal muscular atrophyOrphanet Journal of Rare Diseases, 2011
- The impact of patient expectations on outcomes in four randomized controlled trials of acupuncture in patients with chronic painPain, 2007
- Natural history of denervation in SMA: Relation to age, SMN2 copy number, and functionAnnals of Neurology, 2005
- Identification and characterization of a spinal muscular atrophy-determining geneCell, 1995